Pharmacogenetics and geographical ancestry: implications for drug development and global health.
Understanding and harnessing genomic variation will contribute significantly to improving the health of people in developing countries. We need to explore the nexus between pharmacogenetics, genotyping projects in developing countries, and the evolution of the pharmaceutical industry in both the developed and developing worlds. Here, we argue that, for the foreseeable future, we should focus not on boutique 'personalized' medicine, but on carefully defined differences between populations and ethical ways of using emerging genomics knowledge to develop drugs and improve health.
Daar
Abdallah S
AS
Canadian Program on Genomics and Global Health, University of Toronto Joint Centre for Bioethics, 88 College Street, Toronto, Ontario M5G 1L4, Canada. a.daar@utoronto.ca
Singer
Peter A
PA
D003906:Developing Countries; D023281:Genomics; D014943:Global Health; D010597:Pharmacogenetics; D011159:Population Surveillance; D013678:Technology, Pharmaceutical / Q000639:trends